Oasmia Pharmaceutical AB operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oasmia Pharmaceutical AB with three other
companies in this sector in SWEDEN :
Enzymatica AB (publ)
(2020
sales of 111.25 million Swedish Kronor [US$13.19 million]
of which 100%
was Medical Devices),
Camurus AB
(336.00 million Swedish Kronor [US$39.83 million]
of which 96%
was Sales of development related goods and s), and
Swedencare AB (publ)
(240.30 million Swedish Kronor [US$28.48 million]
of which 54%
was PRODEN PLAQUEOFF).
Sales Analysis.
Sales increased substantially in 2020:
Oasmia Pharmaceutical AB reported sales of SEK 201.84 million (US$23.93 million)
for the
fiscal
year ending
April of 2020.
This
represents
an
increase of 10,094.1%
versus 2019, when the company's sales were SEK 1.98 million.
Sales of Licensing Revenues saw an increase
that was more than double the company's growth rate: sales were up
48,207.4% in 2020, from
SEK 417,000.00 to SEK 201.44 million.
Not all segments of Oasmia Pharmaceutical AB experienced an increase in sales in 2020:
sales of Sales of Goods fell 99.8% to SEK 2,000.00 .